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ABSTRACT 
The therapeutic management of Sjögren syndrome (SjS) has not changed substantially in recent 
decades: treatment decisions remain challenging in clinical practice, without a specific 
therapeutic target beyond the relief of symptoms as the most important goal. In view of this 
scenario, the European League Against Rheumatism (EULAR) promoted and supported an 
international collaborative study (EULAR SS Task Force) aimed at developing the first EULAR 
evidence and consensus-based recommendations for the management of patients with SjS with 
topical and systemic medications. The aim was to develop a rational therapeutic approach to SjS 
patients useful for healthcare professionals, physicians undergoing specialist training, medical 
students, the pharmaceutical industry and drug regulatory organizations following the 2014 
EULAR standardized operating procedures. The Task Force included specialists in rheumatology, 
internal medicine, oral health, ophthalmology, gynaecology, dermatology and epidemiology, 
statisticians, GPs, nurses and patient representatives from 30 countries of the 5 continents. 
Evidence was collected from studies including primary SjS patients fulfilling the 2002/2016 
criteria; when no evidence was available, evidence from studies including associated SjS or 
patients fulfilling previous sets of criteria was considered and extrapolated. The Task Force 
endorsed the presentation of general principles for the management of patients with SjS as 
three overarching, general consensus-based recommendations and 12 specific 
recommendations that form a logical sequence, starting with the management of the central 
triplet of symptoms (dryness, fatigue and pain) followed by the management of systemic 
disease. The recommendations address the use of topical oral (saliva substitutes) and ocular 
(artificial tear drops, topical nonsteroidal anti-inflammatory drugs (NSAIDs), topical 
corticosteroids, topical  cyclosporine A, serum tear drops) therapies, oral muscarinic agonists 
(pilocarpine, cevimeline), hydroxychloroquine, oral glucocorticoids, synthetic 
immunosuppressive agents (cyclophosphamide, azathioprine, methotrexate, leflunomide and 
mycophenolate), and biological therapies (rituximab, abatacept and belimumab). For each 
recommendation, levels of evidence (mostly modest) and Task Force agreement (mostly very 
high) are provided. The 2019 EULAR recommendations are based on the evidence collected in 
the last 16 years in the management of primary 2002 SjS patients and on discussions between a 
large and broadly international Task Force. The recommendations synthesise current thinking on 
SjS treatment in a set of overarching principles and recommendations. We hope that the current 
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recommendations will be broadly applied in clinical practice and/or serve as a template for 
national societies to develop local recommendations. 
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Sjögren syndrome (SjS), a systemic autoimmune disease that affects 1-23 persons per 10,000 
inhabitants in European countries [1], presents with a wide spectrum of clinical manifestations 
and autoantibodies. Antinuclear antibodies are the most frequently detected autoantibodies, 
anti-Ro/SS-A the most specific, and cryoglobulins and hypocomplementaemia the main 
prognostic markers [2]. The histological hallmark is a focal infiltration of the exocrine glands by 
lymphocytes, determined by minor labial salivary gland biopsy. The clinical scenario is 
dominated by sicca syndrome caused by immune-mediated glandular involvement, 
accompanied by fatigue, musculoskeletal pain and systemic features in a significant percentage 
of patients, and complicated by lymphoma in around 2-5% of patients [3]. When SjS appears in a 
previously healthy person, the disease is classified as primary, while patients with concomitant 
systemic autoimmune diseases (SAD) are classified as associated (or secondary) SjS; since this 
distinction only reflects a clinical situation of autoimmune coexistence the term SjS will be 
throughout the manuscript. SjS patients make substantial use of healthcare services, with a 
mean annual total direct cost per patient ranging between £2200 in UK and $20,000 in the US 
[4,5]. 
The therapeutic management of SjS has not changed substantially in recent decades [6] and is 
still based on symptomatic treatment of sicca symptomatology and broad-spectrum 
immunosuppression for systemic disease, with insufficient information on the differential 
efficacy and safety of the therapeutic options available [7]. Treatment decisions remain 
challenging in clinical practice, without a specific therapeutic target beyond the relief of 
symptoms as the most important goal. Therefore there is growing interest in the proposal of 
clinical guidelines by national scientific societies [8–11].  
In 2010, the European League Against Rheumatism (EULAR) promoted and supported an 
international collaborative study (EULAR SS Task Force) aimed at developing disease-specific 
activity indexes in SjS (ESSPRI and ESSDAI scores) [12,13], which are now widely used both 
clinically and in research. A second project, the development of the first EULAR evidence and 
consensus-based recommendations for the management of patients with SjS with topical and 





After approval of the proposal by the EULAR Executive Committee, the convenor (MRC) and co-
convenors (CV, SB, XM) invited international experts with a solid history of clinical research in 
SjS (most of whom were previously involved in the ESSDAI/ESSPRI project) to form part of a 
Steering Committee (SC) and a Task Force (TF), which also included methodologists, patient 
representatives and individuals from all relevant professional groups (Appendix). The aim was to 
develop a rational therapeutic approach to SjS patients that would be useful for healthcare 
professionals, doctors in specialist training, medical students, the pharmaceutical industry and 
drug regulatory organizations following the 2014 EULAR standardized operating procedures 
[14]. Industry involvement was not permitted at any stage of the project. 
 
a) Steering Committee 
The Steering Committee (SC) included 13 rheumatologists, four internal medicine, one primary 
care, and one oral health specialists, one epidemiologist, one statistician, one healthcare 
professional representative and two patient representatives. The SC agreed on some principal 
considerations upfront:  
a) The statements were termed ‘recommendations’ as opposed to ‘guidelines’ or ‘points to 
consider’ because they offer guidance, which needs to be tailored to meet individual 
requirements;  
b) Some general rules and definitions (overarching principles, general recommendations, 
definition of sequential therapeutic schedules, severity or refractoriness) cannot be evidence-
based and were, therefore based on consensus;  
c) The remaining statements were evidence-based, i.e., supported by the highest level of 
evidence possible, limiting statements based only on retrospective data (although for some 
clinical or therapeutic scenarios with no data in controlled studies, this was allowed if the 
amount of retrospective data was considered significant and scientifically reliable); 
recommendations based on data obtained from case reports were not allowed;  
d) Evidence was collected from studies including primary SjS patients fulfilling the 2002/2016 
criteria (SjS-2002) [15,16]. When no evidence was available, evidence from studies including 
associated SjS, patients fulfilling previous sets of criteria or those including a mix of autoimmune 
and non-autoimmune aetiologies was considered and extrapolated (Supplementary Table S1);  
e) The balance between efficacy and side effects was evaluated agent by agent; and  
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f) Although recommendations are primarily supported by the evidence reported in patients with 
primary SjS, the advice on topical and systemic management contained in these guidelines may 
be applicable to patients with associated (or secondary) SjS.  
 
b) Systematic literature review 
A previous systematic literature review (SLR) reported by the convenor in 2010 [7] served to 
provide SC members with a background to initiate discussions and propose research questions 
for the SLR focused on the therapeutic management of SjS. On the basis of the research 
questions, PBZ and SR carried out the SLR between January 1986 and December 2017, with the 
supervision of the convenor and the methodologists. Summary-of-findings (SoF) tables were 
generated and levels of evidence (LoE) were determined according to the study design, using 
the Oxford CEBM standards [17] (Supplementary Table S1). The SoFs of the SLR were presented 
to the SC, whose members formulated a first draft of recommendations based on this 
information, using electronic and cloud-based working strategies to review the literature search, 
making comments and maintaining open communication for electronic discussion and 
amendments. The SLR informing the SC and TF and a detailed description of the methods is 
published separately (SLR paper). 
 
c) Task Force 
The Task Force (Appendix) included 77 specialists in rheumatology, internal medicine, oral 
health, ophthalmology, gynaecology, dermatology and epidemiology, statisticians, GPs, nurses 
and patient representatives from 29 countries of the 5 continents (Argentina, Australia, Brazil, 
Canada, China, Denmark, Egypt, Finland, France, Germany, Greece, Hungary, India, Israel, Italy, 
Japan, Mexico, Norway, Poland, Portugal, Slovenia, South Korea, Spain, Sweden, Switzerland, 
the Netherlands, Turkey, the UK and the US). All Task Force members declared all potential 
conflicts of interest. After presentation of the SLR results and the SC proposals to the TF in the 
first face-to-face meeting, the TF was split into nine breakout working groups (see online 
supplementary text). Each group proposed draft language and diagnostic/therapeutic 
algorithms for the respective recommendations to the whole TF. Safety aspects were addressed 
in each breakout group. Formal economic analyses were not performed, but cost aspects were 
considered throughout the process. Representatives of each breakout group reported the 
results of the respective deliberations and presented proposals for the wording of individual 
 9 
recommendations to the whole TF for further discussion and refinement in the second face-to-
face meeting. 
 
d) Consensus findings 
After the second meeting, a web-based Delphi procedure was carried out using online voting 
[18]. The Delphi procedure was designed by MRC and PBZ, and developed, managed and 
analysed by BK using Google Forms; all clinical experts in SjS included in the TF were invited to 
participate in the Delphi procedure. For an overarching principle or recommendation to be 
accepted for the final document, TF members were asked to grade for priority according to the 
level of importance in the daily therapeutic management of SjS (from 1 as unimportant, no 
priority, no relevance to 5 as very important, a most relevant point, first-order priority); a 
specific section allowed the inclusion of comments suggested to accompany individual items. 
Recommendations scoring ≥ 4 (“important”) by > 80% of participants were accepted; if this 
result was not achieved, the respective text was amended and subjected to a second electronic 
ballot. The approved recommendations were subjected to an anonymous electronic vote on the 
levels of agreement (LoA). Each recommendation was adjudicated on a scale of 0–10 (0, no 
agreement; 10, full agreement).  
The draft of the manuscript was written by MRC and PBZ and was sent to TF members for 
comment and, after incorporating these comments, to the EULAR Executive Committee for 
review and approval. Final remarks were obtained from members of the TF and the Executive 
Committee and addressed in the manuscript (all modifications required approval by the SC), 






As in other EULAR recommendations, the TF endorsed the presentation of general principles for 
the management of patients with SjS as overarching, general consensus-based 
recommendations, since the contents were so generic that there was no requirement to base 
them on the SLR (Table 1). 
 
A. Patients with SjS should be managed at, or in close collaboration with, centres of expertise 
using a multidisciplinary approach (LoE na; LoA 9.2) 
SjS may be a serious systemic disease, not only due to the heavy impact on the health-related 
quality of live (HRQoL) of the predominant symptoms (the triplet of dryness, fatigue and pain), 
but also due to the involvement of internal organs (systemic involvement) and the excess 
mortality caused by cancer (lymphoma). The low frequency of SjS in the general population, 
combined with a heterogeneous glandular/systemic clinical expression, makes it difficult to 
ensure a standardized depth of expertise in managing the disease in non-specialized clinical 
settings. Therefore, we recommend organizing SjS management in and around centres of 
expertise, including professionals with solid clinical experience in assessing patients with SAD. 
Assessment of SjS patients requires expert guidance, not only to confirm the diagnosis by ruling 
out non-autoimmune aetiologies (especially for sicca symptoms), but also to evaluate the extent 
of organs damaged and to design a specific personalized follow-up according to the clinical and 
biological patient phenotype at diagnosis [19]. A multidisciplinary approach involving various 
health professional is essential, with a central role for specialists in autoimmune diseases, who 
should act as the coordinator of diagnostic and therapeutic healthcare processes, based on a 
shared-decision policy between the patient and the specialist. The involvement of primary care 
physicians and other health professionals is highly recommended in the management of SjS 
patients. 
 
B. The first therapeutic approach to dryness should be symptomatic relief using topical 
therapies (LoE na; LoA 8.9) 
More than 95% of SjS patients present with sicca symptoms [20], which have a significant 
impact on the HRQoL [21–23]. Studies that have evaluated the natural history of glandular 
function in primary SjS (summarized by Haldorsen et al) [24] report that, except in early stages 
 11 
of the disease, dysfunction may remain stable for long periods of time (up to 12 years) and have 
a chronic course, and no study has demonstrated that any therapeutic intervention can reverse 
glandular dysfunction and, therefore, can cure sicca symptoms. Since the complete 
disappearance of dryness, which is the desired target for all patients, is at present unreachable, 
the TF recommends exploring the use of other, more realistic outcomes, such as the minimal 
clinically-important improvement (MCII) or the patient-acceptable symptom state (PASS), 
following the corresponding ESSPRI definitions [13], always closely aligned with patient 
education, including coping strategies. The chronic course of SjS means a daily, long-term use of 
therapies and, in this scenario, it is reasonable to recommend the use of therapies with a 
minimum of (or at least tolerable and reversible) side effects. This is overwhelmingly fulfilled by 
topical therapies (see definition in Table 2). Various studies and Cochrane SLRs support the daily 
use of topical therapies for the symptomatic relief of dryness, with a significant improvement in 
HRQoL without significant side effects [7,25,26]. These therapies should be immediately 
initiated after objective confirmation of glandular dysfunction. 
 
C. Systemic therapies may be considered for the treatment of active systemic disease (LoE na; 
LoA 9.1) 
Systemic disease is a key prognostic determinant of SjS and is linked to autoimmune-mediated 
organ/s dysfunction that may eventually become irreversible. The use of systemic 
immunomodulatory/immunosuppressive therapies (glucocorticoids, antimalarials, 
immunosuppressive agents, intravenous immunoglobulins and biologics) should be restricted to 
patients with active systemic disease (see definition in Table 2) but only after a careful organ-by-
organ evaluation of both severity and organ damage, since not all patients with active systemic 
disease will necessarily require systemic therapy (this was why the original wording using 
“should be” was changed to “may be”). As a general rule, the management of systemic features 
in SjS should follow a schedule consisting of a two-stage sequential regimen as used in other 
SAD, including a first intensive immunosuppressive approach targeted to restore organ function 
(induction of remission) as soon as possible, followed by a second therapeutic course aimed at 
maintaining the initial therapeutic response (maintenance of remission). Unfortunately, there 
are no available data in patients with SjS to support specific recommendations on the need for 




The 12 specific recommendations form a logical sequence, starting with the management of the 
central triplet of symptoms (dryness, fatigue and pain) followed by the management of 
systemic, extraglandular disease (Table 1). 
 
1. Baseline evaluation of salivary gland function is recommended before starting treatment 
for oral dryness (LoE 5, LoA 8.7) 
The therapeutic approach to oral dryness should be driven by the baseline measurement of 
salivary glandular function, and not by the patient’s subjective feelings, since environmental and 
personal stressing factors may influence the subjective feeling of dryness [27], which often does 
not match with the objective measurement of glandular function. We recommend the baseline 
evaluation of salivary glandular function by measuring whole salivary flows before starting 
therapeutic interventions, always ruling out SjS-unrelated conditions (i.e. candidiasis, burning 
mouth syndrome); salivary scintigraphy may also be considered [28]. This item elicited 
significant discussions about the specific tests for measuring glandular function (unstimulated 
and stimulated whole salivary flows, UWSF and SWSF, respectively, and salivary scintigraphy), 
especially the use of SWSF and salivary scintigraphy, which were considered as complicated 
tests in daily practice by several TF members, and not always available in all clinical settings. 
 
2. The preferred first therapeutic approach for oral dryness according to salivary gland 
function may be: 2.1. Non-pharmacological stimulation for mild dysfunction; 2.2. 
Pharmacological stimulation for moderate dysfunction*; 2.3. Saliva substitution for severe 
dysfunction (LoE 1a/*1b, LoA 8.7).  
On the basis of the results obtained in the measurement of salivary gland function, the 
therapeutic approach to oral dryness may be initiated based on two mechanisms: salivary gland 
stimulation (non-pharmacological or pharmacological) or saliva substitution (Figure 1) [29]. 
2.1. Non-pharmacological stimulation. In patients with mild glandular dysfunction, we 
recommend non-pharmacological glandular stimulation as the preferred first-line therapeutic 
approach, using gustatory stimulants (sugar-free acidic candies, lozenges, xylitol) and/or 
mechanical stimulants (sugar-free chewing gum) since, in these patients, glandular function can 
be stimulated (Figure 1). With no evidence available for pSjS-2002 patients, evidence was 
extrapolated from a Cochrane SLR [25] focused on the therapeutic management of oral dryness; 
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the authors concluded that all non-pharmacological interventions evaluated relieve subjective 
symptoms to some, unquantified degree, without strong evidence that any intervention was 
more effective than another, although no study evaluated the therapeutic response according 
to the degree of salivary gland dysfunction [25]. 
2.2. Pharmacological stimulation. In patients with moderate glandular dysfunction, 
pharmacological stimulation with muscarinic agonists may be considered. Two drugs 
(pilocarpine and cevimeline) are licensed for the treatment of oral dryness, although only 
pilocarpine is licensed worldwide. The three pivotal RCTs included both primary and associated 
SjS patients fulfilling the 1993 criteria, and found significant improvements in VAS dry mouth 
and salivary flow rates, with a high frequency of adverse events [7]. The available evidence in 
pSjS-2002 patients is limited to one small prospective study using pilocarpine that found 
improvement in subjective but not objective oral outcomes [30], and a second study with no 
detailed information about overall efficacy and safety [31]. A third retrospective study which 
compares pilocarpine and cevimeline, only focused on the safety profile [32], and reported a 
better tolerance profile for cevimeline. The evidence is too limited to make a strong 
recommendation for pSjS-2002 patients (the best level of evidence should be extrapolated from 
RCTs including patients fulfilling the former 1993 criteria). For this reason, and together with the 
unfavourable safety profile of these drugs, we recommend offering a trial of muscarinic agonists 
to patients with moderate glandular dysfunction (or in those with mild dysfunction who are 
refractory or who do not wish to use non-pharmacological stimulation) (LoE 1b, GoR B) (Figure 
1). To reduce the main side effect (excess sweating), and based on clinical practice, some TF 
experts recommended increasing the dose progressively up to 15 to 20mg/day when possible. In 
patients who are intolerant or non-responders to muscarinic agents, some choleretic 
(anetholtrithione) or mucolytic (bromhexine, N-acetylcysteine) agents used as secretagogues in 
SjS since the 1980s may be considered as rescue therapies due to their good safety profile in the 
absence of alternative therapeutic options, and taking into account the limitations of the study 
design and the marginal benefits reported by most studies [7]. According to the SLR results, for 
the treatment of oral dryness we do not recommend the use of hydroxychloroquine (no 
placebo-differences for subjective and objective oral outcomes in the pivotal RCT), oral GCs, 
immunosuppressive agents (overwhelmingly-negative results with excess side effects) or 
rituximab (no placebo-differences for subjective and objective oral outcomes in the two pivotal 
RCT and one meta-analysis)  
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2.3. Saliva substitution. Saliva substitution should be considered the preferred therapeutic 
approach to alleviate symptoms in patients with no residual glandular function (severe glandular 
dysfunction), in whom salivary glands cannot be stimulated, either by pharmacological or non-
pharmacological interventions (Figure 1). The ideal preparation will have a neutral pH and 
contain fluoride and other electrolytes, mimicking the composition of natural saliva; saliva 
substitutes are available commercially in the form of oral sprays, gels and rinses [10]. Only one 
prospective study evaluated pSjS-2002 patients [33] and found no statistically-significant 
placebo-differences for the primary outcome, although significant improvements were reported 
in some subjective oral outcomes, with no side effects reported. Evidence can be extrapolated 
from a Cochrane SLR that evaluated the effectiveness of topical treatments for any-cause dry 
mouth; the review found no superiority for any therapeutic option [25]. In spite of the limited 
evidence available, we recommend their use in the target population because, in the experience 
of TF members, patients often report increased oral comfort without significant side effects 
[10]. Oral gel-like formulations may be useful in patients with an acceptable salivary flow 
output, particularly when they complain about nocturnal oral dryness, although these patients 
often have a poor tolerance to saliva substitutes due to the sticky feeling caused by their 
application, which may be reduced by diluting the saliva substitute. Pre-therapeutic evaluation 
of salivary function may also aid the choice of a specific formulation of saliva substitutes (gel, 
saliva substitute -diluted or not-, mouth rinses), with less thick/dense preparations being 
preferred for patients with a better-preserved glandular function [34]. The preferred first-line 
use of saliva substitutes in patients with no salivary output elicited an intense debate within the 
TF, probably due to the apparent paradox of using a topical therapy in patients with severe 
glandular involvement. Several TF members expressed a dissenting view, stating that saliva 
substitutes should be used in all patients with oral dryness, irrespective of glandular function.  
3. The first-line therapeutic approach to ocular dryness includes artificial tears and ocular 
gels/ointments (LoE 1a, LoA 9.5). 
The first line of therapy for ocular dryness should be volume replacement and lubrication using 
artificial tears (AT) and ocular gels, whose main ingredients are lubricants with a polymeric base 
or viscosity agent (methylcellulose, hyaluronate) with the aim of adding volume to the tear lake, 
increasing the time the AT remain on the ocular surface, and cushioning the ocular surface to 
reduce friction between lid and globe [35]. All SjS studies testing AT (only one in pSjS-2002 
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patients) found significant improvements for both subjective and objective ocular outcomes, 
while a recent Cochrane review on the use of AT for dry eye syndrome showed that they are 
safe and effective [26]. We recommend that all SjS patients presenting with ocular dryness 
and/or abnormal ocular tests should use artificial tears containing methylcellulose or 
hyaluronate at least twice daily, with the frequency increased to as often as hourly, as indicated 
by symptoms and/or objective signs. The use of preservative-free formulations of artificial tears 
is mainly recommended in patients requiring four or more applications per day. Ophthalmic 
ointments are thicker than AT and may be used to provide symptom control overnight; they are 
typically used before bedtime because they produce blurred vision and their use should be 
followed by morning lid hygiene to prevent blepharitis [35].  
 
4. Refractory/severe ocular dryness may be managed using topical immunosuppressive-
containing drops* and serum eye drops (LoE 1a/*1b, LoA 9.1). 
Patients with refractory or severe ocular dryness should be managed by an ophthalmologist 
with substantial experience in corneal disease wherever possible. Refractory ocular dryness is 
defined as patients who do not improve after using the best-available SOC (defined as the 
maximum use of artificial tears and ointments according to the previous recommendation) after 
ruling out other SjS-unrelated ocular processes (i.e. blepharitis), while severity should be 
defined according to the results obtained in a specific ophthalmological evaluation of corneal 
damage by measuring the OSS, together with patient symptoms as assessed by the OSDI (Figure 
2).  
4.1. Topical NSAIDs/corticosteroids. Topical ocular NSAIDs or corticosteroids may be prescribed 
by ophthalmologists as a short-term therapeutic approach (maximum 2-4 weeks), as adverse 
events may occur with continued use of topical NSAIDs (corneal-scleral melts, perforation, 
ulceration and severe keratopathy) or topical corticosteroids (infections, increased intraocular 
pressure and worsening/development of cataracts) [35]. Evidence in pSjS-2002 patients is 
limited to one small case-control study [36] using topical fluorometholone which found no 
significant differences in comparison with topical ocular cyclosporine A. 
4.2. Topical cyclosporine A. In December 2002, an ophthalmic formulation containing 0.05% 
cyclosporine A (CyA) was approved by the FDA to treat dry eye disease in the USA based on the 
results of two RCTs including patients with keratoconjunctivitis sicca (SjS patients were included 
in variable proportions) [7]. There are no specific RCTs carried out in pSjS-2002 [37,38], and only 
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one recent case-control study, which reported no significant differences between groups in 
comparison with topical fluorometholone, with a higher frequency of moderate-to-severe 
transient burning sensation in patients receiving CyA [36]. Ophthalmologists may consider the 
use of ocular CyA drops in patients with refractory or severe ocular dryness requiring repeated 
courses of glucocorticoid tear drops. The promising results of a recent small trial using 
tacrolimus tear drops [39] required further confirmation in large trials.  
4.3. Serum tear drops. In SjS patients, the role of autologous or allogenic serum has been tested 
in small uncontrolled studies showing inconsistent benefits (no improvement in all objective 
ocular outcomes evaluated). A recent Cochrane SLR on the use of serum tear drops for dry eye 
syndrome [40] has confirmed inconsistencies in their possible benefits both for symptoms and 
objective measures, with no evidence of an effect after two weeks of treatment. Only one study 
has been carried out in pSjS-2002 patients, which showed significant improvement in some 
ocular outcomes [41]. The difficulties in preparation, the need to refrigerate the drops, and the 
potential risk of contamination should be taken into account [35,42]. The TF recommended that 
serum tear drops may be considered in patients who are non-responders or intolerant to topical 
CyA tear drops. 
4.4. Rescue therapies. Other therapeutic interventions may be considered after failure of the 
above-mentioned therapies, including topical and systemic therapies. A recent Cochrane SLR 
reviewing the use of plugs for dry eye syndrome [43] found that the evidence was very limited, 
and concluded that improvements in subjective and objective ocular outcomes were 
inconclusive. Two studies have been carried out in primary-2002 SjS patients: the first found no 
significant differences between groups (insertion of plugs vs. artificial tears) [44], and the 
second reported improvement in only 2 of 4 ocular outcomes evaluated [45]. With respect to 
systemic therapies, oral muscarinic agonists may be considered on the basis of the improvement 
of subjective (not objective) ocular outcomes [7]. According to the SLR results, for the treatment 
of ocular dryness we do not recommend the use of hydroxychloroquine (no placebo-differences 
for subjective and objective ocular outcomes in the pivotal RCT), immunosuppressive agents 
(overwhelmingly negative results with excess side effects) or rituximab (no placebo-differences 
for subjective and objective oral outcomes in the two pivotal RCT and one meta-analysis). 
In summary, although patients with refractory/severe ocular dryness may require a more 
intensive ophthalmological follow-up and, probably, more complex therapies, including 
immunosuppressive-based tear drops (topical corticosteroids or cyclosporine A) and serum tear 
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drops, the low level of current evidence for the use of these complex ophthalmological 
therapies in primary SjS-2002 patients do not permit the TF to establish a strong preference 
among the options. The expertise of the ophthalmologist and the specific characteristics of the 
patient will drive both the preferred first-line therapy and the sequential use of the therapeutic 
interventions.  
 
5. Concomitant diseases should be evaluated in patients presenting with fatigue/pain, whose 
severity should be scored using specific tools (LoE 5, LoA 9.0). 
Patients with primary SS often present with general symptoms, of which most frequent are non-
inflammatory joint/muscle pain and fatigue/weakness, which may have a much greater impact 
on the HRQoL than sicca features, as reported in cross-sectional studies [21–23]. Unfortunately, 
these symptoms are very unspecific and could be related to a wide range of concomitant 
pathologies (osteoarthritis, hypothyroidism, hypocortisolism, vitamin deficiencies, depression, 
neoplasia) and even to some systemic complications of systemic SjS (arthritis, anaemia, 
hypokalaemia, osteomalacia, lymphoma, small-fibre neuropathy). A specific comment is needed 
on the association between SjS and some somatic functional syndromes such as chronic fatigue 
syndrome and fibromyalgia, whose peak of incidence occurs in the same population subset as 
SjS (middle-aged women) [19]. No studies have confirmed a solid etiopathogenic autoimmune 
link between SjS and chronic fatigue syndrome/fibromyalgia [46] beyond the evident 
epidemiological overlap. Since the association of these somatic syndromes could heavily 
influence both the patient and physician global health status evaluation, we recommend 
searching for these syndromes using standardized recommendations [47], and measuring the 
severity of pain and fatigue using specific scales such as the corresponding ESSPRI domains, the 
Profile of Fatigue (for measuring fatigue) and the Brief Pain Inventory (for measuring pain) [48]. 
SjS patients may describe various kinds of pain and fatigue, and the use of both general and SjS-
specific questionnaires will permit not only a standardized measurement of their potential 
impact on HRQoL, but consideration of their influence when specific therapeutic interventions 
are initiated [10,49].  
 
6. Consider analgesics or other pain-modifying agents for musculoskeletal pain, taking into 
account the balance between potential benefits and side-effects (LoE 4, LoA 8.9). 
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With respect to SjS-related musculoskeletal pain, a clear pre-therapeutic differentiation must be 
made clinically between joint pain (arthralgia) and joint inflammation (arthritis, tenosynovitis) 
[50]. The ESSDAI score classifies arthralgia in the hands, wrists, ankles and feet accompanied by 
morning stiffness (>30 min) as low articular activity level, always ruling out concomitant 
osteoarthritis. Arthritis is clinically diagnosed on the basis of objective inflammation of ≥ 1 joints 
(heat, redness and swelling in the physical examination of the affected joint) supported by 
ultrasound studies when in doubt, and the ESSDAI score classifies the severity of arthritis 
according to the number of joints involved (moderate <5 joints, high >5) [12]. The therapeutic 
management of arthritis is included in the systemic recommendations.  
a) In patients presenting with acute musculoskeletal pain, consider acetaminophen or NSAIDs 
for symptomatic relief, always for less than 7-10 consecutive days at full dosage and 
considering the side effects and underlying comorbid diseases. In real life, a large 
retrospective study in 188 primary 2002 SjS patients with joint involvement reported that 
nearly one third had a rapid clinical response to the short-term use of analgesics/NSAIDs 
[51]. Topical formulations of NSAIDs (topical diclofenac or ketoprofen) may be effective 
for local pain with fewer side effects [52], but there is no available evidence in SjS patients 
[53].  
b) In patients with frequent episodes of acute musculoskeletal pain, the use of 
hydroxychloroquine has been proposed based on its comparable use in other SAD such as 
SLE. Although uncontrolled studies have reported improvement in joint pain, the pivotal RCT 
failed to demonstrate that hydroxychloroquine improved pain after 24 weeks of treatment 
in comparison with placebo, although a statistical trend was reported (p values between 
0.06 and 0.10) at 12, 24 and 48 weeks) [54]. Taking this positive trend, the lack of reported 
cases of retinal toxicity or severe adverse events, and the lack of pharmaceutical 
alternatives with a similar indication/safety profile, the TF members agreed to consider the 
use of hydroxychloroquine in some patients with frequent episodes of articular pain. In real 
life, the study by Fauchais et al [51] reported the use of hydroxychloroquine in more than 
half the patients presenting with joint involvement. With respect to the use of biological 
agents to treat these symptoms, the data from the two pivotal RCTs [55,56] on the effect of 
rituximab on pain and fatigue reported no significant differences in comparison with 
placebo for both pain and fatigue VAS (although some differences were found at 
intermediate evaluation points in the French study), together with no significant placebo-
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differences in QALY but with a 5-fold greater economic cost [56], while a recent meta-
analysis [57] confirmed no significant differences after combining the results of these trials. 
In addition, a small RCT using anakinra found no significant reduction in fatigue in its 
primary endpoint [58], while the promising results obtained in two small open-label studies 
(<30 patients) using epratuzumab [59] or abatacept [60] must be confirmed in further large 
RCTs. Therefore, we consider that the off-label use of biological agents to treat only 
musculoskeletal pain (even as rescue therapy) is not currently warranted.  
c) In patients with chronic, daily non-inflammatory pain, the management must be completely 
different, avoiding the repeated use of NSAIDs or GCs. The non-pharmacological 
management of pain should be emphasized, instead of going straight to prescribing 
medications for the symptoms. Therefore, the first therapeutic step should be to follow the 
same recommendations as those proposed for general chronic pain, by suggesting that 
physical activity and aerobic exercise are interventions with few adverse events that may 
reduce pain severity and improve physical function [61]. In addition, a small case-control 
study in primary SjS patients showed significant improvement in aerobic capacity, fatigue, 
and ratings of perceived exertion and depression in patients allocated to the exercise group 
[62]. Antidepressants and anticonvulsants may be considered for chronic musculoskeletal 
pain, while patients with chronic neuropathic pain may require the use of gabapentin, 
pregabalin or amitriptyline (paying attention to potential exacerbations of dryness 
symptoms). Recent epidemiological data confirm that opioids must not be used [63].  
7. Treatment of systemic disease should be tailored to organ-specific severity using the ESSDAI 
definitions (LoE 4, LoA 9.0). 
In non-specialized medical settings, primary SjS is often considered a chronic, non-life-
threatening disease that only causes dryness, fatigue and pain. However, systemic involvement 
has been increasingly recognized as a key part of the disease, with a significant weight in 
dictating the prognosis and survival in retrospective studies [64–67]. The development of the 
ESSDAI by the EULAR-SS Task Force Group has provided a helpful, objective instrument to 
measure systemic involvement in primary SS that is accepted worldwide. According to 
overarching principle C, we recommend that the use of systemic therapies (glucocorticoids, 
antimalarials, immunosuppressive agents, intravenous immunoglobulins, biologics) should be 
restricted to patients with active systemic disease (see definitions in Table 2). However, the 
management of systemic features must be tailored to the specific organ involved and the 
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severity evaluated by the ESSDAI [67]. As an overall rule, systemic therapies may be considered 
for most patients presenting with at least moderate activity in one clinical domain, or with a 
global moderate disease activity score (score >5). With respect to the definition of the 
therapeutic response in systemic SjS, the TF recommends using a reduction of ≥3 points in the 
global ESSDAI score [68]. It should also be considered that some systemic manifestations are not 
captured by the ESSDAI, including Ro-associated congenital heart block, Raynaud phenomenon, 
primary pulmonary hypertension, pleuritis, pericarditis, dysautonomia, interstitial cystitis and 
sensorineuronal hearing loss; these features require specific patient-by-patient management.  
 
8. Glucocorticoids should be used at the minimum dose and length of time necessary to 
control active systemic disease (LoE 4, LoA 9.6). 
The frequent use of glucocorticoids (GC) in clinical practice in primary SS patients [67,69,70] is 
not supported by reliable scientific evidence, since no controlled study has specifically evaluated 
their use for systemic disease. Available data come mainly from retrospective studies 
(Supplementary Table S2) and case series/reports, which also highlighted the high rate of GC-
related adverse events. We recommend that GCs should be used at the minimum dose and 
length of time necessary to control active systemic disease, administering pulses of 
methylprednisolone followed by doses of 0.5mg/kg/d or lower as induction therapy in severe 
presentations (Table 2), and doses <0.5mg/kg/d in moderate/less-severe presentations, with a 
final target of withdrawing GCs in inactive patients as soon as possible or at least trying to target 
a maintenance dose of 5mg/daily or less with the aid of GC-sparing immunosuppressive agents 
(see next recommendation). No available data in SjS patients support specific recommendations 
on the rate of de-escalation of the GC dose, or when a GC-sparing agent should be added, or the 
length of GC therapy, although we recommend tapering GCs as rapidly as clinically feasible. We 
recommend to follow the EULAR evidence-based and consensus-based recommendations on 
the management of medium to high-dose glucocorticoid therapy in rheumatic diseases [71]. 
 
9. Synthetic immunosuppressive agents should mainly be used as GC-sparing agents, with no 
evidence supporting the choice of one agent over another (LoE 4, LoA 8.9). 
Based on the potential development of chronic damage in patients with uncontrolled systemic 
disease, some patients may require long-term therapy with GCs, especially those with severe 
organ impairments [67,69,70]. In these patients, the addition of immunosuppressive agents as 
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GC-sparing agents is justified, always weighing the potential benefits and risks. The use of 
immunosuppressive agents in primary SS is based on the same level of evidence as that of GCs, 
since all reported studies (prospective uncontrolled studies, all including less than 50 patients) 
were principally centred on the efficacy in sicca features and laboratory parameters, but not on 
the efficacy in systemic disease, with an unacceptable rate of adverse events (ranging between 
41% and 100%) [7]. The lack of head-to-head studies comparing the efficacy and safety profile of 
immunosuppressive agents in primary SjS-2002 (leflunomide, methotrexate, azathioprine, 
mycophenolate, cyclophosphamide) does not permit a recommendation on the use of one 
agent over another, except when patient characteristics or comorbidities are considered with 
respect to the safety profile. In addition, there is no information available about the dose, route 
of administration and length of treatment, and we recommend a case-by-case evaluation 
following similar rules to those reported for other SAD. Although some TF members suggested 
the use of monotherapy with immunosuppressive agents, there was no final consensus on this 
option due to the lack of studies demonstrating the efficacy of GC-free regimens in SjS, and the 
fact that more than 95% of reported cases using immunosuppressive agents in primary SjS-2002 
received associated GCs (Supplementary Table S2). Several immunomodulatory agents have 
been tested in SS, with marginal benefits or with an unacceptable rate of adverse events and are 
not recommended [7].  
 
10. B-cell targeted therapies may be considered in patients with severe, refractory systemic 
disease (LoE 1b, LoA 8.6). 
The emergence of biological therapies this century has increased the therapeutic 
armamentarium available for treating severe SjS. These new drugs have the highest level of 
evidence among all the drugs tested for SjS, not only because have they have been tested in a 
large number of patients (>1000), but also because most of reported RCTs in primary SjS have 
tested biologics. Unfortunately, their use in clinical practice is clearly limited by the lack of 
licensing. B-cell targeted therapies are the most frequently tested biological drugs, and include 
epratuzumab [59] and belimumab [72,73], although the most widely studied B-cell target 
therapy is rituximab [55,56,74–84].  
Studies with available data on the efficacy of rituximab on systemic involvement have included 
more than 400 patients with primary SjS-2002 (Supplementary Table S3), with a predominant 
use of the regimen of 2 doses of 1 gr each administered 15 days apart [7]. Four main systemic 
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outcomes were evaluated at different follow-up times in these studies: the global therapeutic 
response, organ-specific response, change in the global ESSDAI score and reduction in 
prednisone use. Uncontrolled studies have reported a global response rate of 60-100% for 
systemic features, especially cryoglobulinemic features [74,75,77,78,84]. One small RCT [84] 
reported a significant reduction in reported extraglandular manifestations and improvement of 
musculoskeletal features at weeks 12 and 36 (p=0.029) and vasculitis at week 24 (p=0.03). Four 
studies (two retrospective, one case-control and one prospective) have reported a statistically-
significant reduction in the global baseline ESSDAI score (from 9-20.3 to 2.5-5.2 after treatment) 
[75–78,82]. In the two pivotal RCTs, Devauchelle et al found no differences in the mean ESSDAI 
improvement [55], while Bowman et al [56] reported statistically-significant placebo differences 
at week 36 (p=0.03) and a statistically-significant trend at week 48 (p=0.07) in the log-
transformed ESSDAI score. Three retrospective studies have demonstrated a statistically 
significant reduction in the daily dose of GCs [74,77,78]. In summary, the great majority of 
studies showed efficacy in at least one of the systemic outcomes analysed (global response, 
organ-specific response, ESSDAI reduction, prednisone reduction).  
The results of the BELISS open label trial [72] in 30 pSjS-2002 patients treated with belimumab 
showed a reduction in the mean ESSDAI score from 8.7 to 5.7 at week 28 (p<0.0001), with a 
decrease of at least 4 points in 40% of cases and improvements in parotid swelling in 77% of 
cases; of 5 patients previously refractory to rituximab, belimumab was effective in 3 (60%). In a 
study extension of the 19 patients that completed one year of treatment, a significant 
improvement was maintained [73]. With respect to the safety profile, one severe adverse event 
was reported (pneumococcal meningitis) after 6 infusions of belimumab.  
After intense discussion among the TF members and balancing the positive results of 
uncontrolled studies, the weak evidence reported by RCTs, and the fact that the trials were not 
primarily designed to evaluate the systemic response, we agreed that the use of rituximab may 
be considered (we changed the original wording of “should be”) in patients with severe, 
refractory systemic disease, and that the best indication is probably for symptoms linked to 




11. The systemic organ-specific therapeutic approach may, as a general rule, follow the 
sequential (or combined) use of glucocorticoids, immunosuppressive agents and biologics (LoE 
5, LoA 8.6). 
The recommended general sequential use of the three main categories of immunosuppressive 
agents in SjS is based on a similar approach to that reported for other SAD such as SLE or 
vasculitis, with no controlled studies supporting this approach in SjS. As a general rule, for most 
systemic involvements GCs (see recommendation 8) may be considered the first-line option in 
patients with active systemic disease, and immunosuppressive agents and biologics as 
second/third line options to be used in patients intolerant or refractory to GCs, those with 
severe disease or those in whom long-term GC use is anticipated. In spite of the greater amount 
of scientific evidence data available for rituximab in comparison with GCs and 
immunosuppressive agents, the lack of licensing, the lack of controlled studies for systemic 
disease and the lack of head-to-head comparisons between rituximab and classic 
immunosuppressants (especially with respect to the safety profile) were issues to be 
considered. After an intense discussion among the TF members, the TF agreed to merge the two 
options as second-line therapies (adding a specific note about the use of rituximab as especially 
recommended for associated cryoglobulinemic vasculitis), always with a careful case-by-case 
assessment of the use of rituximab in an off-label context, evaluating potential benefits and 
adverse effects patient-by-patient (Table 2), and taking into account the fact that their use will 
depend on drug availability and national regulations.    
Unfortunately, after analysing the available evidence, no controlled data was identified to 
support a differentiated organ-guided therapeutic approach for systemic SjS, and some TF 
members recommend no strictly adherence to sequential therapy management, with an 
individualised therapeutic approach being preferable. However, on the basis of the results, 
principally from retrospective studies (Supplementary Table S2), together with the clinical 
experience of the TF members, a list of consensus-based algorithms defining SOC and 
second/third line therapies was proposed for each clinical ESSDAI domain (Figure 3a-i); Ro-
associated congenital heart block (not included in the ESSDAI) was also included due to its 
prognostic significance. There was no consensus on the proposal to make recommendations for 
organ-specific maintenance therapeutic regimens. 
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12. Treatment of B-cell lymphoma should be individualized according to the specific 
histological subtype and disease stage (LoE 4, LoA 9.7). 
Among the systemic manifestations of SjS, lymphoma is one of the worst complications, with 
SIRs for B-cell lymphoma ranging between 7 and 9 in population-based studies and between 16 
and 48 in hospital-based studies [86]. Although the vast majority of cells infiltrating the salivary 
glands of patients with primary SjS are T cells, the majority of lymphomas reported are of B-cell 
origin with a ratio between B and T-cell lymphomas of 15:1; three subtypes of B-cell lymphoma 
account for more than 90% of reported cases in primary SjS: MALT lymphoma, other marginal 
zone lymphomas and DLBCL [86]. Following the diagnosis of lymphoma, therapy should be 
individualized according to the specific histological subtype defined according to the WHO 2016 
classification [87] and the corresponding current therapeutic guidelines, with a personalized 
therapeutic approach driven by the haematologist/oncologist. For primary SjS-2002 patients 
diagnosed with low grade haematological neoplasia, some clinicians recommend a watchful 
waiting approach when lymphoma only affects the exocrine glands [88], especially in the 
absence of constitutional symptoms, systemic features or B-cell activation biomarkers [3]. The 
decision to treat low-grade lymphomas or not must be discussed in a multidisciplinary 
committee, taking into account the fact that they are linked to the disease activity and are the 
ultimate stage of autoimmune B-cell activation. Moreover, low grade B-cell lymphomas have a 
potential risk of progression to more aggressive types of lymphoma [3]. In patients with 
disseminated MALT lymphoma or with concomitant high disease activity, chemotherapy may be 
considered on a case-by-case basis [3]. For patients with marginal zone lymphomas (MZL), small 
lymphocytic lymphoma (SLL), and lymphoplasmacytic lymphoma (LPL) in early disease stages (in 
particular, stage I or nonbulky stage II), treatment may include radiotherapy (with or without 
chemotherapy), although a watch-and-wait strategy could be an alternative to spare the side 
effects of therapy [89]. For patients with moderate/high grade haematological neoplasia, 
treatment is based on standard rituximab-based chemotherapy regimens. The benefit of adding 
rituximab to chemotherapy has been demonstrated in a meta-analysis in patients with follicular 
lymphomas, mantle cell lymphomas and other indolent lymphomas [89]. Rituximab plus 
fludarabine (FR) or bendamustine (BR) are the recommended first-line therapy for MZL, SLL and 
LPL; a recent study in 13 patients with pSjS-2002 (77% stage IV) complicated by MZL has 
reported the efficacy of the BR combination in all 13 cases, with improvement in the other SjS 




The EULAR recommendations for the management of SjS with topical and systemic therapies 
management have been developed by a large, multidisciplinary, multiprofessional team. In 
summary, 9 RCTs (only 3 including 120-130 patients), 18 prospective (all including between 10 
and 50 patients) and 5 case-control studies were selected to support the scientific evidence 
presented here. This is a small number of studies that is not comparable with RA or with other, 
more closely-related diseases, such as SLE or systemic vasculitis. Therefore, the evidence 
accumulated in this century reveals SjS as a true orphan disease from a therapeutic point of 
view [57,91], with the absence of any efficacious agent, a situation that is in clear contrast with 
the significant advances achieved in both basic and clinical research during this period. As a 
consequence of the limited evidence available, therapeutic decisions in daily practice are often 
based on a mix of reported expert opinions and personal experience, which may vary widely 
between countries: therefore, the present recommendations are based on the input of experts 
from 16 European countries and wide international representation from the other continents. In 
addition, SjS presents with a wide range of signs and symptoms (not only the key features of 
dryness, fatigue and pain, but also those derived from organ-specific systemic involvements and 
lymphoma), with a large number of different specialties involved and, therefore, with a wide 
variety of potential interventions. Methodologically, we have also taken into account the 
continuous changes in classification criteria since 1986 and, in consequence, the continuous 
changes in the target population classified as primary SjS. For this reason, we decided, in the 
PICOS strategy, to focus on the evidence collected from therapeutic studies including pSjS-2002 
patients, since these criteria have been used for a longer and more-recent period and because 
of their similarity with the recent 2016 ACR/EULAR criteria [16]. 
In SjS, we are very far from the “disease modification” concept as the mainstay of treatment (as 
used in other diseases such as RA, a concept that allows the use of the term DMARD for many 
drugs that have demonstrated the ability to prevent structural damage progression in RA). A 
rapid overview of the LoE that support each statement (Table 1) shows that all 
recommendations for managing oral and ocular dryness are principally supported by evidence 
extrapolated from Cochrane SLRs that evaluated their management in mixed etiological 
populations; on the management/prevention of dryness-related complications (oral ulcers, 
candidiasis, caries/dental complications, ocular infections), the management of dryness other 
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than oral or ocular, or the role of non-therapeutic interventions in dryness, there was a very 
limited number of studies carried out in 2002 primary SS patients, and we recommend following 
published guidelines [9–11,35,92]. With respect to the most frequently used synthetic drugs 
(GCs and immunosuppressive agents), the available evidence came from isolated uncontrolled 
studies. The only exceptions were for hydroxychloroquine and rituximab, which were both 
tested in well-designed RCTs, although there were no statistically-significant differences with 
respect to placebo for the primary outcome (efficacy in dryness, fatigue and pain). With respect 
to systemic disease, the use of rituximab was supported by a large number of studies, mainly 
uncontrolled. We are also very far from defining specific treatment targets (especially searching 
for remission in non-systemic features), but it may be useful to use the EULAR disease activity 
states [68], considering that any higher disease activity has to be regarded as inadequate 
disease control, thus mandating a therapeutic intervention, or that low disease activity achieved 
after therapy may be potentially acceptable for some organs. In any case, as stated in previous 
EULAR recommendations [93], communication with the patient to clarify and agree on the 
treatment goal and the means to attain it is of utmost importance. Monitoring should be 
frequent in patients with systemic active disease, although the frequencies of follow-up 
examinations should be adjusted in accordance with the individual disease activity state [68], 
namely, more frequently, such as monthly, when patients have high disease activity, and less 
frequently, such as every 6–12 months, when patients have low disease activity. 
Lessons should be learned from the first biological tested in primary SjS (infliximab). The 
excellent results of TNF-targeted therapies in RA led to their testing in patients with primary SjS, 
in spite of the large pathological and clinical differences between the two diseases. After the 
report of promising results in small open-label studies (one of which has been recently retracted 
by the authors), the first well-designed RCT showed no differences between the infliximab and 
placebo arms for the primary outcome. The same disappointing results have been obtained for 
other drugs reported as efficacious according to uncontrolled data (hydroxychloroquine and 
rituximab) without significant results for the primary outcomes when tested in RCTs. In SjS trials, 
two common issues may help to explain the negative results. The first is the choice of primary 
end-points. Most studies used composite primary outcomes based mainly on the subjective 
evaluation of dryness, fatigue, pain [94]; the strong influence of personal and environmental 
factors on the intensity of this triad of symptoms could explain the lack of significant differences 
(a higher rate of placebo-related response), together with inadequate patient selection (too low 
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degree of disease activity), the influence of concomitant drugs and the heterogeneity of 
diagnostic tests. The composite ESSDAI to measure systemic activity was used in the most 
recent RCT as a secondary end-point and frequently calculated retrospectively (although one of 
the weaknesses of this outcome could be the difficulty in differentiating activity due to chronic 
damage in different domains). The preliminary results of two new RCT where ESSDAI was the 
primary end-point demonstrated efficacy of the active drug vs. placebo (anti-CD40 and the 
combination of leflunomide and hydroxychloroquine) [95,96]. The second issue is the limited 
number of patients randomized (no more than 50-60 patients per arm), taking into account the 
clinical and immunological heterogeneity of SjS as an SAD (such as SLE or systemic vasculitis); in 
SLE, the pivotal trials that allowed the licensing of belimumab were obtained from two trials 
including nearly 1,000 patients each. Some promising results recently reported in small open-
label studies testing biologics (belimumab, anakinra) must be confirmed in further large well-
designed RCTs, while advance results of a large trial in primary SjS do not indicate a clinical 
benefit of abatacept (96 bis). The current therapeutic pipeline in SjS, as shown by the 
clinicaltrials.gov webpage, is that the biologic therapeutic approach overwhelmingly used in SjS 
until now (targeting B-cell depletion) is shifting towards the evaluation of biologics targeting 
cytokines, T-cells and intracellular signalling pathways [97]. With respect to ongoing trials, 
considerable interest is centred on the BAFF pathway, investigating the effect of mAbs targeting 
BAFF-R or the association between B-cell depletion and BAFF inhibition. In addition, studies are 
testing inhibition of other pathways activating B cells. Lastly, four ongoing trials are testing other 
pathways or the use of other cytokine-based therapies including tocilizumab, abatacept, 
filgotinib (a JAK inhibitor) and human recombinant Il-2.  
Therapeutic research in SjS should probably be reconsidered in order to explore new pathogenic 
targets outside the glandular tissue (i.e. neuroendocrine pathways), and to search for a more 
personalized therapeutic approach based on genetic, clinical, immunological and/or 
histopathological characteristics. It is not improbable that future RCTs would benefit from more 
selected patient cohorts, possibly including newly diagnosed SjS patients, the findings of early 
salivary gland ultrasound changes [98–100], or evidence of early high disease activity at 
diagnosis [20] before permanent damage has been established and the changes are still 
reversible. Patients with sicca-limited disease differ from those with systemic disease, as do 
immune- negative patients from those carrying Ro autoantibodies or cryoglobulins, while recent 
etiopathogenic studies are beginning to divide SjS patients according to the genetic profile 
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between those with or without a predominant IFN-I gene expression signature [101,102] (103). 
Sensitivity analyses searching for a differentiated response to therapies in these subsets of 
patients (sicca-limited vs. systemic; Ro+ vs. Ro-; positive vs. negative salivary gland biopsy; 
positive vs. negative IFN-I signature) might help to better delineate the therapeutic effect of a 
drug tested in primary SjS, although this would require a greater number of patients randomized 
than those included in reported trials.  
In conclusion, the 2019 EULAR recommendations are based on the recent evidence collected on 
the management of primary SjS patients and on discussions by a large, broadly-based 
international Task Force. The recommendations synthesise current thinking on SjS treatment in 
a set of overarching principles and recommendations. These have been informed by a specific 
SLR on the efficacy and safety of topical and systemic interventions, although the high-quality 
scientific evidence focused on primary SjS patients fulfilling the currently-accepted sets of 
criteria was limited. However, the Task Force is convinced that adhering to these 
recommendations, including shared decision-making, assessing disease activity regularly with 
the ESSDAI instrument, and applying the sequence of drugs as proposed, will improve overall 
outcomes in a clear majority of patients with SjS. New research information on treatment 
strategies, predictive markers and other aspects will soon become available and will probably 
require an update of the recommendations in coming years (see Future Agenda box). Until then, 
we hope that the current recommendations will be broadly applied in clinical practice and/or 
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Table 1. Overarching (A-C) and specific (1-12) recommendations. 
 




A. Patients with SjS should be managed at, or in close collaboration with, centres of 
expertise following a multidisciplinary approach 
na NA 90 9.2 
B. The first therapeutic approach for dryness should be symptomatic relief using topical 
therapies 
na NA 93 8.9 
C. Systemic therapies may be considered for the treatment of active systemic disease na NA 90 9.1 
1. Baseline evaluation of salivary gland function is recommended before starting treatment 
for oral dryness 
5 D 81 8.7 
2. The preferred first therapeutic approach for oral dryness according to salivary gland 
function may be:  
2.1. Non-pharmacological stimulation for mild dysfunction;  
2.2. Pharmacological stimulation* for moderate dysfunction;  
2.3. Saliva substitution for severe dysfunction 
1a/*1b B 88 8.7 
3. The first-line therapeutic approach to ocular dryness includes the use of artificial tears 
and ocular gels/ointments 
1a B 98 9.5 
4. Refractory/severe ocular dryness may be managed using topical immunosuppressive-
containing drops* and autologous serum eye drops 
1a/*1b B/D 94 9.1 
5. Concomitant diseases should be evaluated in patients presenting with fatigue/pain, 
whose severity should be scored using specific tools 
5 D 93 9.0 
6. Consider analgesics or other pain-modifying agents for musculoskeletal pain, considering 
the balance between potential benefits and side-effects 
4 C 89 8.9 
7. Treatment of systemic disease should be tailored to organ-specific severity using the 
ESSDAI definitions 
4 C 89 9.0 
8. Glucocorticoids should be used at the minimum dose and length of time necessary to 
control active systemic disease 
4 C 85 9.6 
9. Immunosuppressive agents should be mainly used as GC-sparing agents, with no evidence 
supporting the choice of one agent over another 
4 C 82 8.9 
10. B-cell targeted therapies may be considered in patients with severe, refractory systemic 
disease 
1b B 98 8.6 
11. The systemic organ-specific therapeutic approach may follow, as a general rule, the 
sequential (or combined) use of glucocorticoids, immunosuppressive agents and biologics 
5 D 98 8.6 
12. Treatment of B-cell lymphoma should be individualized according to the specific 
histological subtype and disease stage 
4 C 88 9.7 
NA: not applicable; Levels of evidence (LoE) and grades of recommendations (GoR) according to the Oxford Centre for Evidence-
based Medicine – Levels of Evidence (March 2009). Vote (%): % of participants scoring the recommendation as at least 




Table 2. Glossary and definitions 
 
Term Definition Examples 
1. Nomenclature of therapies 
 




1.2. Systemic therapies 
 
 
1.1. Interventions directly 
applied to the mucosal surfaces 
involved 
 
1.2. Drugs administered orally or 













2. Disease activity terms 
 

























2.5. Therapeutic response 
 
 
2.1. Disease involvement that 
affects or has affected any of 
the organs/systems included in 
the clinESSDAI score 
 






2.3. Patients with ESSDAI score 
>14, or high activity in any of 
the ESSDAI domains with a 




2.4. Systemic manifestation/s 






2.5. Decrease of ≥ 3 points in 
the global ESSDAI score 
 
 





2.2. Systemic activity is classified 
as low if ESSDAI is 1-4 (if not 
only due to biological domain), 
moderate between 5-13, and 
high ≥ 14.  
 
2.3. Lymphadenopathy and 
lymphoma, articular, cutaneous, 
pulmonary, renal, muscular 
central and peripheral 
neurological and haematological 
domains.  
 
2.4. Due to the diversity of 
systemic manifestations, SOC 
(first-line therapeutic approach) 
has been defined for each 
systemic manifestation (Figure 
3) 
- 











3.1. Refractory ocular dryness is 
defined as not improvement 
after using the best-available 
SOC and ruling out other SjS-
unrelated processes,  
3.2. Severity should be defined 
after a specific ophthalmological 
 
 
3.1. SOC defined as the 
maximum use of artificial tears 







evaluation of corneal damage 
by:  
3.2. Measurement of the OSS 
and OSDI ocular scores 
4. Recommended instruments 
of measure 
 
4.1. Salivary gland function 
 






4.5. Quality of life 
 




4.1. UWSF, SWSF 
 
4.2. OSS, OSDI 
 
4.3. ESSPRI domains, ProFAD 
 




4.6. ESSDAI, clinESSDAI 
 
 
5. Potential life-threatening 
systemic manifestations 
5.1. Cutaneous domain 
 
5.2. Pulmonary domain 
 





5.4. Muscular domain 
 












5.7. Haematological domain 
5.1. Diffuse vasculitis with ulcers 
 
5.2. ILD with NHYA III/IV 
 





5.4. Muscular involvement with 
severe weakness 
5.5. Neuropathy (including 
ganglionopathy and 




5.6. Demyelinating disease with 
motor deficit; cerebral vasculitis 




5.7. Severe haemolytic anaemia 






BOX. Research agenda 
 Is there a specific, differentiated treatment of lymphomas related to SjS? 
 Is combination therapy a potential intervention to explore in SjS? 
 Exploring targeted therapies against Th17 cytokines, IFN-α, RORɣt expression, Janus kinases 
(JAKS), STATs and mTOR intracellular pathways or IL-1. 
 Searching for predictive factors of biological response 
 Potential use of sequential or intralesional use of biological therapies 
 Encouraging the development of new and innovative therapies 
 In what proportion of systemic patients is induction therapy with current therapeutic 
options effective in inducing sustained remission? 
 Is the use of immunosuppressive and biologic agents safe and efficacious in the absence of 
concomitant glucocorticoid treatment? 
 How safe and efficacious is the off-label use of other biologics after rituximab has failed? 
 Can we find predictors of differential response to the synthetic and biological drugs used in 
SjS? 
 Can we predict who will maintain remission after withdrawal of glucocorticoids? 
 Will we be able to develop precision (personalised, stratified) medicine approaches in SjS? 
(interferon signature +/-; immunological or histopathological markers +/-) 
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Figure 1. Algorithm of glandular function assessment and therapeutic approach in patients with 
primary SjS presenting with oral dryness 
Figure 2. Algorithm of glandular function assessment and therapeutic approach in patients with 
primary SjS presenting with ocular dryness 
*Consider neuropathic pain if OSS ≤1 
**Additional criteria for severity: 1) Impaired visual function (photophobia, visual acuity 
modification or low contrast sensitivity); 2) Blepharospasm (secondary to ocular inflammation); 
3) Severe meibomian gland disease or eyelid inflammation  
***For short-term indications (2-4 weeks) 
OSS, Ocular Staining Score (Whitcher JP, et al. Am J Ophthalmol. 2010;149:405-15).  
OSDI, Ocular Surface Disease Index  
Adapted from Baudouin C, et al. Br J Ophthalmol 2014;98:1168-1176 
Figure 3 (a to i). Algorithm for the therapeutic approach to patients with primary SjS presenting 
with organ-specific systemic involvements 
NSAIDs: no longer than 7-10 days 
HCQ: hydroxychloroquine 200mg/day 
GC (recommended dose in mg/kg/day); short-term course whenever possible; consider methylprednisolone 
pulses in severe cases 
ID: immunosuppressive agents, no head-to-head comparisons 
CyC: cyclophosphamide pulses 0.5 g/15day (maximum 6 pulses) 
Rituximab: rituximab 1g/15day (x2) 
BLM: belimumab; 10 mg/kg (0, 2 and 4w, and then every 4w) 
ABA: abatacept 0, 2, 4w and every 4w 
ivIG: intravenous immunoglobulins 0.4-2g/kg 5 days 
Pex: plasma exchanges 
 
